GERMANTOWN, Md.--(BUSINESS WIRE)--Senseonics Holdings, Inc. (NYSE American: SENS), a medical technology company focused on the development and commercialization of transformative glucose monitoring products, today announced the company plans to participate in the upcoming Canaccord Genuity Growth Conference in Boston, MA.
Senseonics’ management is scheduled to present Thursday, August 9, 2018 at 1:30pm ET. Interested parties may access a live and recorded webcast of the presentation on the “Investor Relations” section of the company’s website at www.senseonics.com.
About Senseonics
Senseonics Holdings, Inc. is a medical technology company focused on the design, development and commercialization of glucose monitoring products designed to help people with diabetes confidently live their lives with ease. Senseonics’ Eversense System is a long-term, implantable device, which includes a small sensor, smart transmitter and mobile application. Based on fluorescence sensing technology, the sensor is designed to be inserted subcutaneously and communicate with the smart transmitter to wirelessly transmit glucose levels to a mobile device. After insertion, the sensor is designed to continually and accurately measure glucose levels. The Eversense System is approved in the United States and indicated for 90 days of continuous use and the Eversense XL System is approved in EMEA and indicated for up to 180 days of continuous use. For more information on Senseonics, please visit www.senseonics.com.
